This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krueger, W. A.
Right arrow Articles by Unertl, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krueger, W. A.
Right arrow Articles by Unertl, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 1998, p. 2421-2424, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous Hemodiafiltration

W. A. Krueger,1,* T. H. Schroeder,1 M. Hutchison,2 E. Hoffmann,1 H.-J. Dieterich,1 A. Heininger,1 C. Erley,3 A. Wehrle,1 and K. Unertl1

Department of Anesthesiology1 and Department of Internal Medicine,3 Tübingen University Hospital, Tübingen, Germany, and ZENECA Pharmaceuticals,2 Mereside, Alderly Park, Macclesfield, Cheshire, United Kingdom

Received 29 December 1997/Returned for modification 6 April 1998/Accepted 22 June 1998

The pharmacokinetics of meropenem were studied in nine anuric critically ill patients treated by continuous venovenous hemodiafiltration. Peak levels after infusion of 1,000 mg over 30 min amounted to 103.2 ± 45.9 µg/ml, and trough levels at 12 h were 9.6 ± 3.8 µg/ml. A dosage of 1,000 mg of meropenem twice a day provides plasma drug levels covering intermediately susceptible microorganisms. Further reductions of the dosage might be appropriate for highly susceptible bacteria or when renal replacement therapies with lower clearances are applied.

* Corresponding author. Present address: Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, 181 Longwood Ave., Boston, MA 02115. Phone: (617) 525-2680. Fax: (617) 731-1541. E-mail: wkrueger{at}rics.bwh.harvard.edu.

Antimicrobial Agents and Chemotherapy, September 1998, p. 2421-2424, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Li, A. M. M. Y., Gomersall, C. D., Choi, G., Tian, Q., Joynt, G. M., Lipman, J. (2009). A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?. J Antimicrob Chemother 64: 929-937 [Abstract] [Full Text]  
  • Krueger, W. A., Kempf, V. A. J., Peiffer, M., Nagele, U., Unertl, K. E., Schroeder, T. H. (2008). Treatment with Tigecycline of Recurrent Urosepsis Caused by Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli. J. Clin. Microbiol. 46: 817-820 [Abstract] [Full Text]  
  • Nguyen, T. H., Hoppe-Tichy, T., Geiss, H. K., Rastall, A. C., Swoboda, S., Schmidt, J., Weigand, M. A. (2007). Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 60: 100-106 [Abstract] [Full Text]  
  • Isla, A., Maynar, J., Sanchez-Izquierdo, J. A., Gascon, A. R., Arzuaga, A., Corral, E., Pedraz, J. L. (2005). Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients. J Clin Pharmacol 45: 1294-1304 [Abstract] [Full Text]  
  • Krueger, W. A., Bulitta, J., Kinzig-Schippers, M., Landersdorfer, C., Holzgrabe, U., Naber, K. G., Drusano, G. L., Sorgel, F. (2005). Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers. Antimicrob. Agents Chemother. 49: 1881-1889 [Abstract] [Full Text]  
  • Robatel, C., Decosterd, L. A., Biollaz, J., Eckert, P., Schaller, M. D., Buclin, T. (2003). Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. J Clin Pharmacol 43: 1329-1340 [Abstract] [Full Text]  
  • Mueller, S. C., Majcher-Peszynska, J., Hickstein, H., Francke, A., Pertschy, A., Schulz, M., Mundkowski, R., Drewelow, B. (2002). Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis. Antimicrob. Agents Chemother. 46: 1557-1560 [Abstract] [Full Text]  
  • Valtonen, M., Tiula, E., Backman, J. T., Neuvonen, P. J. (2000). Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 45: 701-704 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»